FDA Approves Bixlenvo for HIV-1 Switch Therapy in Virologically Suppressed Adults

The FDA has approved bictegravir 75 mg/lenacapavir 50 mg (Bixlenvo; Gilead) as a complete switch regimen for adults with HIV-1 who are virologically suppressed on stable antiretroviral therapy (ART). The once-daily tablet may offer an alternative for some patients receiving complex, multitablet regimens, although eligibility requires no known or suspected resistance to either component, according to a press release from Gilead.¹

“Bixlenvo offers a new once-daily STR designed for the evolving needs of people with HIV,” Chloe Orkin, MD, lead primary investigator for the phase 3 ARTISTRY-1 trial and clinical professor at Queen Mary University of London, in the press release. She identified preexisting resistance and tolerability as potential reasons that patients may be unable to use other single-tablet regimens.

The approval applies only to adults with HIV-1 RNA below 50 copies/mL who are replacing an existing stable regimen. It does not establish Bixlenvo as initial therapy for treatment-naive patients or as an option for individuals with active virologic failure.¹

Phase 3 Evidence Supports Switch Indication

The decision was based on the phase 3 ARTISTRY-1 and ARTISTRY-2 studies, which evaluated whether virologically suppressed adults could switch to bictegravir/lenacapavir while maintaining suppression.²˒³ According to Gilead, both trials demonstrated comparable maintenance of virologic suppression through week 48, with no new or significant safety concerns identified.¹ Absolute response rates and prespecified comparison margins were not included in the approval announcement.

ARTISTRY-1 focused on heavily treatment-experienced adults receiving complex regimens. Participants had a median age of 60 years and a median ART duration of 28 years. At baseline, they were taking between 2 and 11 pills daily; approximately 40% received ART more than once per day. Historical nucleoside reverse transcriptase inhibitor resistance was reported in 67%, and 81% were using a complex regimen because of antiretroviral resistance.¹

Switching was also associated with improvements in selected fasting lipid measures and patient-reported treatment satisfaction, the company reported. ARTISTRY-2 evaluated switching from bictegravir/emtricitabine/tenofovir alafenamide and found no significant effect on weight.¹ These secondary findings require interpretation alongside the full trial methods and multiplicity analyses.

Bixlenvo combines 2 antiretroviral classes. Bictegravir is an integrase strand transfer inhibitor that blocks integration of viral DNA into the host genome. Lenacapavir is a capsid inhibitor that disrupts multiple stages of the HIV life cycle and does not share cross-resistance with existing antiretroviral classes.¹

Treatment requires a 2-day oral initiation regimen. On days 1 and 2, patients take 1 Bixlenvo tablet plus 600 mg of oral Sunlenca (lenacapavir). Beginning on day 3, Bixlenvo is taken once daily, with or without food.⁴

The most common adverse reactions were headache (4%), nausea (3%), and diarrhea (2%). Concomitant administration with dofetilide or strong CYP3A inducers is contraindicated. Clinicians should review concomitant medications carefully because CYP3A, UGT1A1, and P-glycoprotein interactions may alter exposure to the regimen.⁴

Clinically, the approval creates a simplification option for selected treatment-experienced patients without sacrificing the requirement for a fully active regimen. However, the evidence is limited to patients already suppressed, and follow-up reported in the announcement extends to 48 weeks. Longer-term durability, resistance after virologic rebound, adherence in routine practice, and comparative effects on metabolic outcomes remain important questions. Bictegravir/lenacapavir is not approved outside the United States.¹

References

1. Gilead Sciences. U.S. FDA approves Gilead’s Bixlenvo, a new once-daily single tablet option for virologically suppressed adults with HIV, including those on complex regimens. Business Wire. Published August 27, 2026. https://www.businesswire.com/news/home/20260817093045/en/U.S.-FDA-Approves-Gileads-Bixlenvo-a-New-Once-Daily-Single-Tablet-Option-for-Virologically-Suppressed-Adults-With-HIV-Including-Those-on-Complex-Regimens
2. ClinicalTrials.gov. ARTISTRY-1. NCT05502341. Accessed August 27, 2026.
3. ClinicalTrials.gov. ARTISTRY-2. NCT06333808. Accessed August 27, 2026.
4. Gilead Sciences. Bixlenvo (bictegravir and lenacapavir) prescribing information. 2026.